Vorasidenib Maintenance for IDH Mutant Astrocytoma | MicrobiomeTrials← Back to trialsNCT06809322
Vorasidenib Maintenance for IDH Mutant Astrocytoma
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-01-16Est. Completion: 2035-04-13
Enrollment target: 468 participants Locations- Medical University of Innsbruck, Innsbruck, Austria
- Kepler University Hospital - Neuromed campus, Linz, Austria
- Medical University of Vienna, Vienna, Austria
- Universitair Ziekenhuis Brussel, Brussels, Belgium
- Ghent University Hospital, Ghent, Belgium
- U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium
- Masaryk Memorial Cancer Institute, Brno, Czechia
- Universitary hospital Bordeaux France, Bordeaux, France
- CHU Lyon - Hopital neurologique Pierre Wertheimer, Lyon, France
- Marseille APHM, Marseille, France
- Assistance Publique Hopitaux de Paris APHP - Sorbonne, Paris, France
- Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France
- Universitaskliniken Bonn, Bonn, Germany
- University Hospital Frankfurt -Senckenberg Institute of Neurooncology, Frankfurt, Germany
- NNeurology department heidelberg, Heidelberg, Germany
- Mannheim University Hospital, Mannheim, Germany
- Universitaetsklinikum Regensburg, Regensburg, Germany
Other microbiome trials you might be interested in
Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of…
Chicago, United StatesEst. completion Sep 2028
Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-MutantRecurrent Astrocytoma, IDH-Mutant
Bellaria Hospital, IRCCS Istituto delle Scienze Neurologiche - AUSL di Bologna, Bologna, ItalyVeneto Institute of Oncology, Padova, ItalySapienza University, Roma, ItalyAOU Citta della Salute e della Scienza di Torino, Torino, ItalyAmsterdam UMC location VUMC, Amsterdam, NetherlandsAcademisch Ziekenhuis Maastricht, Maastricht, NetherlandsErasmus MC, Rotterdam, NetherlandsHospital de Sant Pau i La Santa Creu, Barcelona, SpainVall de Hebron Hospital, Barcelona, SpainHospital Universitario 12 de Octubre, Madrid, SpainUniversity Hospital Basel, Basel, SwitzerlandUniversity Hospital Zurich, Zurich, SwitzerlandQueen Elizabeth Hospital Birmingham, Birmingham, United KingdomThe Christie NHS Foundation Trust, Manchester, United KingdomClatterbridge Cancer Centre, Metropolitan Borough of Wirral, United KingdomRoyal Marsden Hospital, Surrey Quays, United KingdomRecurrent Astrocytoma, IDH-Mutant, Grade 3
Recurrent Astrocytoma, IDH-Mutant, Grade 4
Recurrent Glioblastoma, IDH-Wildtype
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in tr…
Duarte, United StatesEst. completion Jun 30, 2027